Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1989-06-08
1991-08-06
Lee, Lester L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530322, A61K 3702, C07K 900
Patent
active
050378040
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to an agent for preventing and treating thrombocytopenia which comprises, as an active ingredient, a muramyldipeptide derivative represented by the formula (I): ##STR3## wherein X represents an amino acid residue selected from L-alanine, L-serine and L-valine, Y represents ##STR4## wherein R.sub.1 represents a carboxyl group, n represents an integer of 1 to 6, A represents a saturated aliphatic hydrocarbon group having 7 to 29 carbon atoms which may have branched chains, and Acyl represents an acyl group having 2 to 6 carbon atoms.
TECHNICAL BACKGROUND
Multipotential stem cells, which can differentiate to granulocytes, monocytes (macrophages), red blood cells, platelets, lymphocytes, exist in the bone marrow of higher animals such as human and mouse. The stem cells differentiate to precursory cells and the cells differentiate to the above blood cells. On the differentiation to these blood cells, several specific growth factors have been known to function to each blood cell's differentiation. For example, Interleukin-3 functions to the multipotential stem cells to induce the differentiation thereof to precursory granulocytes, and the granulocyte growth factors such as granulocyte-colony stimulating factor (G-CSF, etc.) function to the precursory cells to induce the differentiation thereof and to mature into granulocytes. With respect to the platelets, precursory cells such as megakaryocytes and platelet growth factor (MK-CSF) participate in the platelets. However, the details thereof have not been clarified.
Of various platelets which are considered to have maturation function, platelets have a significant role to maintain the health independently or in cooperation with other blood cells. Therefore, when the differentiation to platelets is inhibited, some diseases caused by reduction of platelet numbers appear.
Examples of such diseases include symptomatic thrombocytopenia, idiophatic thrombocytopenia and the like caused by medical agents (an anticancer agent, etc.), radiation, blood diseases, etc., and more specific symptoms thereof include bleeding, coagulation defect and the like.
Conventionally, as the treating method for such various thrombocytopenia, only platelets transfusion which is complicated and expensive has been used. Thus, there was no agent for the prevention and treatment of such symptoms.
The compounds of the present invention are disclosed in Japanese Patent Publication No. 62-27079 filed by the applicant as having an excellent adjuvant activity and/or preventing and treating effects on infection by microorganisms. However, it has been unknown that the compounds of the formula (I) are effective for the prevention and treatment of thrombocytopenia.
DISCLOSURE OF THE INVENTION
As a result of extensive studies on the compounds of formula (I) above, the present inventors found that the compounds exhibit excellent effects on prevention and treatment of thrombocytopenia and completed the present invention.
That is, the present invention relates to an agent for preventing and treating thrombocytopenia which comprises a compound of the formula (I) as an active ingredient.
Pharmaceutical preparations for administering the compound of the formula (I) include tablets, capsules, powders, granules, injections, suppositories, sprays, dermal preparations and the like. These preparations can be prepared by known pharmaceutical techniques using appropriate additives such as excipients, e.g., corn starch, lactose, mannitol, etc., binders, e.g., hydroxypropyl cellulose, polyvinyl pyrrolidone, etc., disintegrators, e.g., low substituted hydroxypropyl cellulose, crystalline cellulose, etc., and lubricants, e.g., talc, magnesium stearate, etc. If desired, the preparations of the present invention can be a slow release preparation which can be prepared using known pharmaceutical techniques.
The pharmaceutical agent of the present invention thus prepared can be administered orally or parenterally. The dose level usually ranges from 100 to 400 .mu.g/day for adult in c
REFERENCES:
patent: 4357322 (1982-11-01), Rooks, II et al.
patent: 4382080 (1983-05-01), Shiba et al.
patent: 4684625 (1987-08-01), Eppstein et al.
patent: 4780313 (1988-10-01), Koichiro et al.
patent: 4895835 (1990-01-01), Hasegawa
Inoue Atsuo
Masaoka Toru
Masuo Ken
Nakayasu Toshiro
Takayanagi Teruo
Daiichi Seiyaku Co., Ltd.
Lee Lester L.
LandOfFree
Agent for preventing and treating thrombocytopenia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent for preventing and treating thrombocytopenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for preventing and treating thrombocytopenia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1987037